touchIN CONVERSATION

Achieving individualized glycemic targets in patients with T2D: What are the key considerations?



Disclaimer

- Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions
- The presenting faculty have been advised by USF Health and touchIME to ensure that they disclose any such references made to unlabelled or unapproved use
- No endorsement by USF Health and touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in USF Health or touchIME activities
- USF Health and touchIME accepts no responsibility for errors or omissions







Dr Joanna Van Diabetes Research Center Tustin, CA, USA

Dr Vincent Woo University of Manitoba Winnipeg, Manitoba, Canada



What are the challenges of achieving glycemic control in patients with T2D and how can they be overcome?



Dr Joanna Van





Poor glycemic control is the leading cause of diabetes-related complications and death, and is directly related to higher total healthcare, hospitalization and medication costs.^{2,3}



1. Kosiborod M, et al. Cardiovasc Diabetol. 2018;17:150; 2. Mata-Cases M, et al. Diabetes Care. 2020;43:751-8; 3. Mamo Y, et al. BMC Endocr Disord. 2019;19:91.

• What are the obstacles to achieving glycemic targets?

Patient-related

Denial of disease

Treatment costs

Fear of needles

Adherence

- Lack of awareness of progressive nature
- Lack of education on glycemic control
 - Fear of treatment side effects



Clinical Inertia

Physician-related

- Time constraints
- Concerns over cost of therapy/testing
- Reactive instead of proactive care
- Lack of understanding of new therapies
- Lack of guidance on individualized therapy



Healthcare system-related

- No clinical guidelines
- No visit planning
- No active outreach to patients
- No team approach to care
- Poor communication between physician and staff



How can individualized glycemic targets for patients with T2D be set and implemented in clinical practice?



Dr Joanna Van





• How many patients globally achieve A1c targets of <7.0%?





Which factors influence the selection of an optimal A1c target?

Individualized A1c target

		More stringent	7% Less stringent
Non modifiable	Comorbidities	None	Severe/multiple
	Disease duration	Short	Long
	Life expectancy	High	Low
	Risk of hypoglycemia and other AEs	Low	High
	Vascular complications	None	Severe/multiple
Possibly modifiable	Patient's approach	Good self-care	Therapy burden concern
	Resources and support	Good	Poor



What are the optimal A1c targets for different patient groups?

Individualized A1c target



A1c, glycated hemoglobin.

3. American Diabetes Association. Diabetes Care. 2021;44(Suppl. 1):S168-79.

1. American Diabetes Association. *Diabetes Care.* 2021;44(Suppl. 1):S73–84; 2. American Diabetes Association. *Clin Diabetes* 2020;38:10–38;

ENDOCRINOLOGY®

What treatment options are available to help safely achieve glycemic targets in patients with T2D?



Dr Joanna Van



If A1c target is not achieved with metformin after 3 months¹



If A1c above target consider other therapies, including basal insulin

A1c, glycated hemoglobin; ASCVD, atherosclerotic cardiovascular disease; CKD, chronic kidney disease; CVD, cardiovascular disease; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1, glucagon-like peptide-1; HF, heart failure; RA, receptor agonist; SGLT2i, sodium–glucose co-transporter 2 inhibitor; SU, sulfonylurea; TZD, thiazolidinedione.



1. American Diabetes Association. *Diabetes Care.* 2021;44(Suppl. 1):S111–24.